SEC Comment Letter for Elicio Therapeutics, Inc. (ELTX) (CIK 0001601485) (ELTX) — Nov 15, 2024
Elicio Therapeutics, Inc. (ELTX) (CIK 0001601485)
Date: Nov. 15, 2024 · CIK: 0001601485 · Accession: 0000000000-24-012681
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283199
Letter
November 15, 2024 Robert Connelly President & Chief Executive Officer Elicio Therapeutics, Inc. 451 D Street, 5th Floor Boston, MA 02210 Re:Elicio Therapeutics, Inc. Registration Statement on Form S-3 Filed November 13, 2024 File No. 333-283199 Dear Robert Connelly: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:William C. Hicks, Esq.
Show Raw Text
November 15, 2024
Robert Connelly
President & Chief Executive Officer
Elicio Therapeutics, Inc.
451 D Street, 5th Floor
Boston, MA 02210
Re:Elicio Therapeutics, Inc.
Registration Statement on Form S-3
Filed November 13, 2024
File No. 333-283199
Dear Robert Connelly:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:William C. Hicks, Esq.